Valneva SE 2014 IR
The report highlights Valneva's progress in 2014 as a vaccine biotech company following its 2013 merger. Key achievements include clinical trial advancements for its Pseudomonas aeruginosa and Clostridium difficile vaccine candidates, and the first-ever marketing approvals for vaccines produced in its EB66 cell line in Japan and Europe. Financially, the company increased its revenues and grants to EUR 42.4 million, while reducing its pro forma operating loss through cost synergies. Additionally, Valneva announced the acquisition of Crucell Sweden AB and the Dukoral vaccine in early 2015 to complement its travel vaccine portfolio.
Company: Valneva SE
Sector: Health Care
Country: France
Year: 2014
Type: IR
Pages: 414
Valneva SE
Registration Document
The report highlights Valneva's progress in 2014 as a vaccine biotech company following its 2013 merger. Key achievements include clinical trial advancements for its Pseudomonas aeruginosa and Clostridium difficile vaccine candidates, and the first-ever marketing approvals for vaccines produced in its EB66 cell line in Japan and Europe. Financially, the company increased its revenues and grants to EUR 42.4 million, while reducing its pro forma operating loss through cost synergies. Additionally, Valneva announced the acquisition of Crucell Sweden AB and the Dukoral vaccine in early 2015 to complement its travel vaccine portfolio.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2014
Reporting Period
Jan 1, 2014 - Dec 31, 2014
Fiscal Year
2014
Published
Jun 16, 2015
Type
Integrated Report
Language
English
Pages
File Size
Standards & Assurance
Reporting Standards
Materiality Assessment
Assurance
Assurance Provider
Assurance Standard
ESG Data?Experimental — AI-extracted data, may contain inaccuracies
Employees